SAGE Therapeutics (SAGE) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Sage Therapeutics (SAGE) PT Lowered to $15 at Stifel
August 1, 2024 6:40 AM EDTStifel analyst Paul Matteis lowered the price target on Sage Therapeutics (NASDAQ: SAGE) to $15.00 (from $20.00) while maintaining a Hold rating.
The analyst comments "Zurzuvae continues to launch reasonably well in PPD, coming in a hair above consensus despite a significant inventory drawdown. Meanwhile... More
